Spots Global Cancer Trial Database for chronic myeloid leukemia, chronic phase
Every month we try and update this database with for chronic myeloid leukemia, chronic phase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | NCT04006847 | Chronic Myeloid... | Eicosapentaenoi... Tyrosine kinase... | 18 Years - | Milton S. Hershey Medical Center | |
| Efficacy and Safety of Nilotinib in CML-CP | NCT03332511 | Chronic Myeloid... | Nilotinib | 19 Years - | Seoul National University Hospital | |
| CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | NCT06163430 | Chronic Myeloid... Chronic Myeloid... | TERN-701 | 18 Years - | Terns, Inc. | |
| CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia | NCT06163430 | Chronic Myeloid... Chronic Myeloid... | TERN-701 | 18 Years - | Terns, Inc. | |
| Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) | NCT04160546 | Chronic Myeloid... | Ponatinib 15 MG Acetylsalicylic... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia | NCT03882281 | Chronic Myeloid... | HQP1351 | 18 Years - 55 Years | Ascentage Pharma Group Inc. | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Nilotinib for First-line Newly Diagnosed CML-CP Patients | NCT03942094 | Chronic Myeloid... Nilotinib | Nilotinib | 18 Years - | Shenzhen Second People's Hospital | |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT04126681 | Chronic Myeloid... | HQP1351 Hydroxyurea or ... Homoharringtoni... Imatinib, Dasat... | 18 Years - | Ascentage Pharma Group Inc. | |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT04126681 | Chronic Myeloid... | HQP1351 Hydroxyurea or ... Homoharringtoni... Imatinib, Dasat... | 18 Years - | Ascentage Pharma Group Inc. | |
| A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia | NCT06368414 | Chronic Myeloid... | Asciminib | 19 Years - | Korean Society of Hematology | |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | NCT04677439 | Flumatinib Chronic Myeloid... Imatinib | Flumatinib | 18 Years - | Shenzhen Second People's Hospital | |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | NCT04677439 | Flumatinib Chronic Myeloid... Imatinib | Flumatinib | 18 Years - | Shenzhen Second People's Hospital | |
| Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | NCT03722420 | Chronic Myeloid... | Radotinib Imatinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose | NCT03933852 | Chronic Myeloid... | 18 Years - | University of Jena | ||
| Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | NCT03885830 | CML, Chronic Ph... CML (Chronic My... CML - Philadelp... Chronic Myeloid... Chronic Myeloid... | Bosutinib Dasatinib Imatinib Nilotinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Ponatinib in CML Patients in Chronic Phase | NCT06119269 | Chronic Myeloid... | Therapeutic dru... Molecular Respo... | 18 Years - | University of Pisa | |
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | NCT03610971 | Chronic Phase C... Chronic Myeloid... | Ruxolitinib BCR-ABL Tyrosin... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" | NCT05543161 | Chronic Myeloid... | 18 Years - | Sohag University | ||
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia | NCT03882281 | Chronic Myeloid... | HQP1351 | 18 Years - 55 Years | Ascentage Pharma Group Inc. | |
| A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | NCT03459534 | Chronic Myeloid... CML, Chronic Ph... CML, Refractory CML - Philadelp... | Radotinib HCl | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" | NCT05543161 | Chronic Myeloid... | 18 Years - | Sohag University | ||
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | NCT04677439 | Flumatinib Chronic Myeloid... Imatinib | Flumatinib | 18 Years - | Shenzhen Second People's Hospital | |
| The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia | NCT06233890 | Chronic Myeloid... Chronic Myeloid... Fatigue Sleep Disturban... | Motion watch | 18 Years - 70 Years | Imperial College Healthcare NHS Trust | |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| Ponatinib in CML Patients in Chronic Phase | NCT06119269 | Chronic Myeloid... | Therapeutic dru... Molecular Respo... | 18 Years - | University of Pisa | |
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | NCT05311943 | Olverembatinib Chronic Myeloid... Tyrosine Kinase... | olverembatinib | 18 Years - 75 Years | Shenzhen Second People's Hospital | |
| A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia | NCT06368414 | Chronic Myeloid... | Asciminib | 19 Years - | Korean Society of Hematology | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | NCT05311943 | Olverembatinib Chronic Myeloid... Tyrosine Kinase... | olverembatinib | 18 Years - 75 Years | Shenzhen Second People's Hospital | |
| The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia | NCT06233890 | Chronic Myeloid... Chronic Myeloid... Fatigue Sleep Disturban... | Motion watch | 18 Years - 70 Years | Imperial College Healthcare NHS Trust | |
| Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia | NCT03882281 | Chronic Myeloid... | HQP1351 | 18 Years - 55 Years | Ascentage Pharma Group Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
